Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancer.

Autor:	Hurkmans DP; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands d.hurkmans@erasmusmc.nl.; Department of Pulmonology, Erasmus University Medical Center, Rotterdam, The Netherlands., Basak EA; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Schepers N; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Oomen-De Hoop E; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Van der Leest CH; Department of Pulmonology, Amphia Hospital, Breda, The Netherlands., El Bouazzaoui S; Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, The Netherlands., Bins S; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Koolen SLW; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.; Departmemt of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, The Netherlands., Sleijfer S; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Van der Veldt AAM; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.; Department of Radiology & Nuclear Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands., Debets R; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Van Schaik RHN; Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, The Netherlands., Aerts JGJV; Department of Pulmonology, Erasmus University Medical Center, Rotterdam, The Netherlands., Mathijssen RHJ; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Jazyk:	angličtina
Zdroj:	Journal for immunotherapy of cancer [J Immunother Cancer] 2020 May; Vol. 8 (1).
DOI:	10.1136/jitc-2020-000586
Abstrakt:	Background: A minority of patients with advanced non-small-cell lung cancer (NSCLC) benefit from treatment with immune checkpoint inhibitors (ICIs). Ineffective effector function of activated T and NK cells may lead to reduced tumor cell death, even when these activated effector cells are released from their immune checkpoint brake. Hence, in this study we aimed to assess the association of baseline serum granzyme B, as well as germline variation of the GZMB gene, with clinical outcome to programmed cell death protein 1 (PD-1) blockade. Methods: A total of 347 patients with stage IV NSCLC who started nivolumab treatment between June 2013 and June 2017 were prospectively included. Baseline serum and whole blood was available, allowing for protein quantification and targeted DNA sequencing. Clinical outcome was based on best overall response (BOR) according to Response Evaluation Criteria in Solid Tumors, V.1.1, progression-free survival (PFS), and overall survival (OS). Results: Patients with low serum levels of granzyme B had worse PFS (HR: 1.96; 95% CI: 1.12 to 3.43; p=0.018) and worse OS (HR: 2.08; 95% CI: 1.12 to 3.87; p=0.021) than patients with high baseline serum levels. To validate the findings, germline variation of GZMB rs8192917 was assessed. Patients with homozygous and heterozygous variants of GZMB rs8192917 had worse BOR (OR: 1.60; 95% CI: 1.01 to 2.52; p=0.044) and worse PFS (HR: 1.38; 95% CI:1.02 to 1.87; p=0.036) than wild types. Conclusions: A low baseline serum level of granzyme B and germline variation of GZMB was associated with worse clinical outcome in NSCLC, emphasizing the relevance and additional value of monitoring germline genetic variations which mirror cytotoxic functions of T cells in ICI therapy. Trail Registration Number: Dutch Trial Registry (NL6828). Competing Interests: Competing interests: CHvdL reports non-financial support from BMS, MSD, Roche, Boehringer Ingelheim and AstraZeneca outside the submitted work. AAMvdV reports support from BMS, MSD, Sanofi, Roche, Novartis, Pfizer, Pierre Fabre, Ipsen, Eisai and Bayer outside the submitted work. JA reports personal fees from MSD, BMS, Amphera, Eli-Lilly, Takeda, Bayer, Roche, Boehringer Ingelheim, AstraZeneca outside the submitted work, and has a patent allogenic tumor cell lysate licensed to Amphera, a patent combination immunotherapy in cancer and a patent biomarker for immunotherapy pending. RHJM reports grants and non-financial support from Astellas, Bayer and Boehringer Ingelheim, grants from Cristal Therapeutics and Pamgene, grants and personal fees from Novartis, Servier, grants and non-financial support from Pfizer, grants from Roche, Sanofi, outside the submitted work. (© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu